GlassScriptPhysician profile
Barbara Sumbatian
NPI 1790768448
$1,441.01
in general payments reported to CMS, 2019-2025
15 companies · $817 in 2025
The $817 reported for 2025 was more than what 83% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.69 · 2021: $396 · 2024: $211 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.96 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.38 | 2020-2025 | Caplyta |
| Harmony Biosciences LLC | $177.21 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $133.99 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $129.95 | 2024-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $129.80 | 2025 | |
| Neurocrine Biosciences, INC. | $119.37 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $115.45 | 2024-2025 | Uzedy |
| Abbvie INC. | $95.09 | 2025 | |
| Janssen Pharmaceuticals, INC | $69.44 | 2024-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $55.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.90 | 2024-2025 | Trintellix |
| Avadel Cns Pharmaceuticals, LLC | $33.69 | 2025 | Lumryz |
| Collegium Pharmaceutical, INC. | $18.76 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $15.89 | 2025 | Fanapt |
| Lundbeck LLC | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Sumbatian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.